iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. We leverage our deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer.

Our innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes. The first antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism, currently progressing in multiple indications in collaboration with GSK. The Company is also advancing inupadenant, a next-generation adenosine A2A receptor antagonist tailored to overcome cancer immunosuppression into proof-of concept trials in several indications following encouraging single-agent activity in Phase 1.

iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.

SEC Filings

Filing date	Form	Description	Filing Group	View
Oct 12, 2023	4	Statement of changes in beneficial ownership of securities	3,4,5	View HTML 0001209191-23-052709.pdf 0001209191-23-052709.rtf 0001209191-23-052709.xls
Aug 25, 2023	4	Statement of changes in beneficial ownership of securities	3,4,5	View HTML 0000895345-23-000524.pdf 0000895345-23-000524.rtf 0000895345-23-000524.xls
Aug 23, 2023	144	Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing	Other	View HTML 0000895345-23-000522.pdf 0000895345-23-000522.rtf 0000895345-23-000522.xls
Aug 08, 2023	10-Q	Quarterly report which provides a continuing view of a company's financial position	Quarterly Filings	View HTML 0000950170-23-039341.pdf 0000950170-23-039341.rtf 0000950170-23-039341.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Jun 26, 2023	8-K	Report of unscheduled material events or corporate event	Current Reports	View HTML 0000950170-23-029730.pdf 0000950170-23-029730.rtf 0000950170-23-029730.xls EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
Jun 20, 2023	8-K	Report of unscheduled material events or corporate event	Current Reports	View HTML 0000950170-23-028774.pdf 0000950170-23-028774.rtf 0000950170-23-028774.xls EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
Jun 15, 2023	4	Statement of changes in beneficial ownership of securities	3,4,5	View HTML 0001209191-23-037587.pdf 0001209191-23-037587.rtf 0001209191-23-037587.xls
Jun 15, 2023	4	Statement of changes in beneficial ownership of securities	3,4,5	View HTML 0001209191-23-037590.pdf 0001209191-23-037590.rtf 0001209191-23-037590.xls
Jun 15, 2023	4	Statement of changes in beneficial ownership of securities	3,4,5	View HTML 0001209191-23-037588.pdf 0001209191-23-037588.rtf 0001209191-23-037588.xls
Jun 15, 2023	4	Statement of changes in beneficial ownership of securities	3,4,5	View HTML 0001209191-23-037593.pdf 0001209191-23-037593.rtf 0001209191-23-037593.xls

Data provided by Kaleidoscope.

At iTeos we are pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics.

Our pipeline

Our differentiated development approach is driven by biologic rationale and clinical need utilizing our IO candidates in intra-portfolio combinations and with programs of external collaborators.

Explore our pipeline

About Us

Driven by a culture of scientific innovation, collaboration and excellence, together we discover and deliver breakthrough immunotherapies to improve and extend the lives of people with cancer.

Meet our team

For investors

SEC Filings

Our pipeline

About Us